Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBF-680 for Late Asthmatic Response
NCT02635945Phase 2Completed
- Sponsor
- Palobiofarma
- Start
- Apr 2016
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PBF-680 in asthma (2 arms), sponsored by Palobiofarma. Primary endpoint: Late Asthmatic Response. Started Apr 2016; status: completed.
02
Drugs
PBF-680
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02635945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02635945.